<DOC>
	<DOC>NCT01425294</DOC>
	<brief_summary>This study is a post-authorisation pharmacoepidemiology study, committed to Center for Drug Evaluation (CDE) and State Food and Drug Administration (SFDA), in order to provide more efficacy and safety data about Faslodex 250mg in real life clinical practice in China. The objective of the post marketing study is to explore the efficacy and tolerability of Fulvestrant (FASLODEXâ„¢)250 mg in postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy or disease progression on therapy with an anti-estrogen.</brief_summary>
	<brief_title>Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment</brief_title>
	<detailed_description>A Multicenter, non-interventional, prospective study to collect efficacy and safety data in Chinese patients who have received Faslodex 250mg treatment under the condition of actual usage in clinical practice</detailed_description>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Chinese postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer Failure to previous antiestrogen therapy, already received Faslodex 250mg treatment as determined by treating physician. The prescription of the Faslodex is clearly separated from the decision to include the subject in the NIS, and is part of normal medical practice. The recruitment of the patient to the study should be within 1 month of the first Faslodex injection. Provision of subject informed consent. If participating in any controlled clinical trial, the subject cannot take part in this study. Hypersensitivity to the active substance, or to any of the other excipients. Pregnancy and lactation, or severe hepatic impairment.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chinese post-menopausal women</keyword>
	<keyword>oestrogen receptor-positive locally advanced</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>fulvestrant 250 mg</keyword>
	<keyword>failure to adjuvant anti-oestrogen therapy</keyword>
</DOC>